Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
| Revenue (TTM) | $6.30B |
| Gross Profit (TTM) | $4.91B |
| EBITDA | $1.90B |
| Operating Margin | 31.20% |
| Return on Equity | 10.50% |
| Return on Assets | 8.27% |
| Revenue/Share (TTM) | $10.81 |
| Book Value | $17.90 |
| Price-to-Book | 5.26 |
| Price-to-Sales (TTM) | 8.55 |
| EV/Revenue | 8.15 |
| EV/EBITDA | 32.95 |
| Quarterly Earnings Growth (YoY) | 8.20% |
| Quarterly Revenue Growth (YoY) | 16.70% |
| Shares Outstanding | $575.80M |
| Float | $573.99M |
| % Insiders | 0.18% |
| % Institutions | 94.12% |
Volatility is currently contracting
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
NEW YORK--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's leadership in advancing high-quality scientific evidence and innovating for patients. These new data – spanning aortic, mitral and tricuspid therapies – provide further understanding of the complexity of structural heart disease and the need for innovative treatment options.
EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense today announced the launch of the SWH1530VP, a next-generation dual-enclave 100/40 Gigabit Ethernet switch engineered to provide secure, deterministic, and high-performance networking for modern Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance, Reconnaissance (C5ISR), Electronic Warfare (EW), and edge computing applications. Aligned with SOSA™, CMOSS, and OpenVPX™ standards, the 3U VPX module combines advanced La.
During the quarter, we initiated new positions in Edwards Lifesciences, Eli Lilly and Roblox. In addition to Linde, Shopify and Amazon, we also added to Woodward and Spotify during the quarter. We ended our investment campaigns in Netflix, Snowflake and RELX during the quarter.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026. Bernard Zovighian, chief executive officer, will participate in a fireside chat at 3:40 p.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible later the same day. About Edwards Lifesciences.
Modine Manufacturing led the way during the quarter, benefiting from secular demand in data center cooling and a well received spinoff of Modine Manufacturing's auto cooling business. Coming out of 2025, Adeia reported record revenue and profitability, supported by a surge in IP licensing activity. AtriCure remains well positioned given its first-mover advantage and deep integration within surgical workflows despite near-term competitive concerns from Edwards Lifesciences.
Edwards Lifesciences beats on Q1 earnings, matches revenue estimates, lifts 2026 outlook as TAVR and TMTT growth accelerates; shares rise on stronger guidance and margin expansion.
Edwards Lifesciences Corporation (EW) Q1 2026 Earnings Call Transcript
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2026. Highlights and Outlook Q1 sales grew 16.7% to $1.65 billion1, constant currency2 sales grew 12.7% Q1 TAVR sales grew 14.4% to $1.20 billion1; constant currency2 sales grew 11.0% Q1 TMTT sales of $173 million1,3, driven by repair and replacement therapies Q1 EPS of $0.661; adjusted2 EPS of $0.781 Raising FY 2026 constant currency2 sales growth guidance to 9% to.
EW heads into Q1 earnings with TAVR strength, rising estimates and momentum in mitral and tricuspid therapies shaping expectations.
